SurModics to Attend CL King's 9th Annual
Best Ideas Conference on September 14

September 13, 2011 at 12:38 AM EDT

EDEN PRAIRIE, Minn., Sep 12, 2011 (BUSINESS WIRE) --

SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will participate in CL King's 9th Annual Best Ideas Conference in New York City on Wednesday, September 14, 2011. Gary Maharaj, SurModics' President and Chief Executive Officer, and Timothy Arens, Vice President of Finance and interim Chief Financial Officer, will discuss the Company's strategy and business conditions during a formal presentation beginning at 2:15 pm EDT.

The presentation will be available via webcast by visiting the investor relations portion of the Company's website at on the day of the Conference and clicking the webcast icon. In addition, the Conference audio and slide presentation will be archived on the Company's website following the meeting.

About SurModics, Inc.

SurModics' vision is to extend and improve the lives of patients through technology innovation. The Company partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Core offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics is headquartered in Eden Prairie, Minnesota and its SurModics Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

SOURCE: SurModics, Inc.

SurModics, Inc.
Timothy Arens, (952) 500-7056
Vice President of Finance and interim Chief Financial Officer